title: Effects of lipopolysaccharide and phenylbutazone on gastric contents in the horse.
abstract: BACKGROUND
  Endotoxaemia causes a disruption of gastrointestinal motility in the horse but there is no information on its effects on gastric secretion. Lipopolysaccharide (LPS) administration is known to affect gastric secretion in other species.
  
  
  OBJECTIVE
  That LPS, a toxic component of Gram-negative bacteria, would reduce gastric acid secretion and that pretreatment with phenylbutazone (PBZ) would block the effects of LPS.
  
  
  METHODS
  The effects of LPS and PBZ on gastric contents were investigated in fasted, mature horses, with permanent gastric cannulae. Horses were pretreated with either saline or PBZ 15 mins before a 60 min infusion of either LPS or saline. Gastric contents were collected at 15 min intervals for 3 h, beginning 15 mins after the start of the LPS or saline infusion.
  
  
  RESULTS
  Lipopolysaccharide significantly decreased gastric acid output, [K+] and potassium output and increased [Na+] and sodium output. Phenylbutazone did not affect basal gastric acid secretion but decreased LPS-induced changes in the secreted volume, [Na+] and sodium output.
  
  
  CONCLUSIONS
  This study provides evidence that LPS affects gastric acid secretion in the horse and that these LPS-induced changes are mediated, in part, by prostaglandins.
  
  
  CONCLUSIONS
  Lipopolysaccharide administration can induce changes in the composition of gastric contents in the horse but further work is needed to determine the source of these changes.
authors.affiliation: College of Veterinary Medicine, PO Box 1071, The University of Tennessee, Knoxville, Tennessee 37901, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Doherty
authors.forename: F M
authors.initials: FM
authors.lastname: Andrews
authors.forename: J T
authors.initials: JT
authors.lastname: Blackford
authors.forename: B W
authors.initials: BW
authors.lastname: Rohrbach
authors.forename: A
authors.initials: A
authors.lastname: Sandin
authors.forename: A M
authors.initials: AM
authors.lastname: Saxton
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005766:Gastrointestinal Contents / Q000737:chemistry / Q000187:drug effects*; D006736:Horses / Q000502:physiology*; D006863:Hydrogen-Ion Concentration; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology*; D011188:Potassium / Q000378:metabolism; D011897:Random Allocation; D012964:Sodium / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D008070:Lipopolysaccharides; D012964:Sodium; D010653:Phenylbutazone; D011188:Potassium